CII
NBIX icon

Capital International Inc’s Neurocrine Biosciences NBIX Stock Holding History

Capital International Inc’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-18,566
Closed -$1.58M – 306
2021
Q4 		$1.58M Sell
18,566
-272,138
-94% -$25M 0.01% 264
2021
Q3 		$27.9M Sell
290,704
-46,763
-14% -$4.42M 0.27% 109
2021
Q2 		$32.8M Sell
337,467
-19,907
-6% -$1.91M 0.29% 113
2021
Q1 		$34.8M Sell
357,374
-40,605
-10% -$4.26M 0.32% 111
2020
Q4 		$38.1M Sell
397,979
-7,975
-2% -$770K 0.35% 103
2020
Q3 		$39M Sell
405,954
-83,510
-17% -$9.66M 0.43% 84
2020
Q2 		$59.7M Buy
489,464
+7,068
+1% +$781K 0.73% 43
2020
Q1 		$41.8M Sell
482,396
-40,419
-8% -$3.96M 0.7% 59
2019
Q4 		$56.2M Sell
522,815
-7,969
-2% -$834K 0.78% 49
2019
Q3 		$47.8M Buy
530,784
+510,286
+2,489% +$47.7M 0.72% 56
2019
Q2 		$1.73M Buy
20,498
+1,348
+7% +$111K 0.12% 133
2019
Q1 		$1.69M Buy
19,150
+3,500
+22% +$293K 0.2% 96
2018
Q4 		$1.12M Buy
+15,650
New +$1.5M 0.15% 112

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Capital International Inc's NBIX Position: Q1 2022 in Review

Capital International Inc sold out of Neurocrine Biosciences (NBIX) in Q1 2022, closing a stake of 18,566 shares — an estimated $1.58M sold.

Capital International Inc first reported a position in NBIX in Q4 2018 and held it in 13 quarters. The position peaked at $59.7M in Q2 2020. 428 funds tracked by Wall St. Rank hold NBIX as of Q1 2022.

  • Capital International Inc reported no remaining Neurocrine Biosciences position as of Q1 2022 after selling out during the quarter.
  • Capital International Inc sold 18,566 Neurocrine Biosciences shares in Q1 2022, an estimated $1.58M.
  • Capital International Inc first reported a position in Neurocrine Biosciences in Q4 2018 and held it in 13 quarters.
  • Capital International Inc's Neurocrine Biosciences position peaked at $59.7M in Q2 2020.
  • 428 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2022.

Based on Capital International Inc's 13F filing for Q1 2022, filed 16 May 2022.